Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.55 |
| ▸ | HTR7 | P34969 | 7/20 | 0.55 |
| ▸ | DRD2 | P14416 | 5/20 | 0.55 |
| ▸ | HTR6 | P50406 | 4/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6407537 | 0.99 | HTR1A (0.55) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL4528941 | 0.90 | DRD2 (0.64) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL6211876 | 0.90 | HTR1A (0.59) | HTR1AHTR7DRD2HTR6HTR2A | |
| Hydrochloric Acid SCHEMBL4520908 | 0.89 | DRD2 (0.63) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL5175286 | 0.88 | ADRA1A (0.55) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL6211445 | 0.88 | DRD2 (0.52) | HTR1AHTR7DRD2HTR6HTR2A | |
| Hydrochloric Acid SCHEMBL6213630 | 0.87 | ADRA1A (0.54) | HTR1AHTR7DRD2HTR6HTR2A | |
| Hydrochloric Acid SCHEMBL6214323 | 0.87 | DRD2 (0.51) | HTR1AHTR7DRD2HTR6HTR2A | |
| Phosphoric Acid SCHEMBL5422467 | 0.87 | HTR1A (0.63) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL4522586 | 0.86 | HTR1A (0.51) | HTR1AHTR7DRD2HTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1746998-A1 | COMBINATION THERAPY FOR LOWER URINARY TRACT SYMPTOMS | RANBAXY LABORATORIES, LTD. (IN) | 2007-01-31 | — | — | EP | claimed |
| WO-2005092341-A1 | COMBINATION THERAPY FOR LOWER URINARY TRACT SYMPTOMS | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-06 | — | — | WO | claimed |
| EP-1495000-A4 | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE A1A ADRENOCEPTOR BLOCKERS | RANBAXY LAB LTD (IN) | 2005-10-05 | — | — | EP | claimed |
| EP-1495000-A1 | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE A1A ADRENOCEPTOR BLOCKERS | RANBAXY LABORATORIES, LTD. (IN) | 2005-01-12 | — | — | EP | claimed |
| WO-2003084928-A1 | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE Α1Α ADRENOCEPTOR BLOCKERS | RANBAXY LABORATORIES LIMITED (IN) | 2003-10-16 | — | — | WO | claimed |
| US-20050228180-A1 | Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-13 | — | — | US | disclosed |
| EP-1495000-A4 | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE A1A ADRENOCEPTOR BLOCKERS | RANBAXY LAB LTD (IN) | 2005-10-05 | — | — | EP | disclosed |
| EP-1495000-A1 | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE A1A ADRENOCEPTOR BLOCKERS | RANBAXY LABORATORIES, LTD. (IN) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084928-A1 | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE Α1Α ADRENOCEPTOR BLOCKERS | RANBAXY LABORATORIES LIMITED (IN) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228180-A1 | Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers | ADRA1A, ADRB1, ADRA1B | HTR1A 54/4885HTR7 802/4885DRD2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.